ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2925

Factors Associated with Early Damage Accrual in Patients with Systemic Lupus Erythematosus: 12-Month Preliminary Results from the Inception Cohort of the Multicenter Early Lupus Project

Matteo Piga1, Fabiana Figus1, Francesca Bellisai2, Silvano Bettio3, Alessandra Bortoluzzi4, Laura Coladonato5, Fabrizio Conti6, Andrea Doria3, Mauro Galeazzi2, Marcello Govoni4, Florenzo Iannone7, Annamaria Iuliano8, Marta Mosca9, Imma Prevete8, Gian Domenico Sebastiani8, Francesca Romana Spinelli10, Chiara Tani9 and Alessandro Mathieu1, 1University of Cagliari, Cagliari, Italy, 2University of Siena, Siena, Italy, 3Department of Medicine-DIMED, University of Padova, Padova, Italy, 4University of Ferrara, Ferrara, Italy, 5DIM, Rheumatology Unit, Bari, Italy, 6Rheumatology Unit, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy, 7Interdisciplinary Department of Medicine (DIM), Rheumatology Unit, University of Bari, Bari, Italy, 8Osp. San Camillo, Roma, Italy, 9University of Pisa, Pisa, Italy, 10Sapienza University of Rome, Rome, Italy

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Cardiovascular disease, neuropsychiatric disorders and outcomes, SLE

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 10, 2015

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Preventing organ damage is a major challenge in management of Systemic Lupus Erythematosus (SLE). Few data are available on factors related to development of damage in early stages of the disease. This study aim to evaluate the early damage accrual and factors associated with development of damage in the Early Lupus Project, a prospectively followed-up inception cohort of SLE patients diagnosed within 12 months since fulfillment of four or more 1997 ACR classification criteria

Methods:

The development and progression of damage assessed by the SLICC/ACR Damage Index (SDI) were prospectively recorded during the first year of the disease. SDI represent irreversible damage occurred after onset of SLE and being present for at least 6 months; by definition, it scores 0 at disease onset.

Using univariate analysis, we assessed the contribution of covariates collected at baseline (demographic, serological, clinical by BILAG2004 domains, disease activity by ECLAM index) in the development of damage (SDI from 0 to ≥1) within 12 months since disease onset.  Stepwise regression models were fitted with covariates with p<0.1 to identify factors independently associated with development of damage. 

Results:

A total of 119 patients (93.3% Caucasians, 18 males) were eligible for this study having available data at 12 months of disease. Mean age and mean disease duration since recognition of 4 ACR criteria were 36.7±14.1 years and 2.5±3.9 months (median = 1 month; IR 0-3.1), respectively. Twenty-eight (23.5%) and 31 (26.0%) patients, had an SDI score ≥1 after 6 and 12 months since disease onset (Table 1), respectively.

Univariate analysis revealed that dyslipidemia (p=0.01), anti-Beta2glicoproteinI antibodies positivity (p=0.01), active cardiorespiratory involvement (p=0.02) and high disease activity calculated by ECLAM  (p=0.05) registered at baseline were associated with development of damage. However, older age at diagnosis (p<0.01; OR 1.1 95% CI 1.0-1.3), higher number of active BILAG2004 clinical domain (p<0.01; OR 1.7 95% CI 1.2 – 2.4) and neuropsychiatric involvement at baseline (p<0.01; OR 6.7 95% CI 1.4-32.2) were the only independent risk factors for early development of damage in this cohort.

No influence of active renal involvement and medications prescribed at baseline was detected in our cohort, likely because they most contribute to development of late-onset damage.

Table 1. Distribution at 6 and 12 months and prevalence of organ damage stratified according to the SDI domains at 12 months of disease.

 

Prevalence (patients)

SLICC 6 Months (median; IR range)

  SLICC = 0

  SLICC = 1

  SLICC > 1

0 (0-0)

76.5% (91)

16.8% (20)

6.7% (8)

SLICC 12 Months (median; IR range)

  SLICC = 0

  SLICC = 1

  SLICC > 1

0 (0-1)

73.9% (88)

18.5% (22)

7.6% (9)

SDI domains

Neuropsychiatric

  Cerebrovascular accident

  Cognitive impairment

  Peripheral neuropathy

  Psychosis

 

10.1% (12)

5.9% (7)

3.4% (4)

1.7% (2)

0.8% (1)

Ocular

  Cataract

  Retinal change

5.9% (7)

3.4% (4)

2.5% (3)

Miscellanea

  Malignancy

  Diabetes

5.0% (6)

4.2% (5)

0.8% (1)

Cardiac

  Pericarditis or pericardiectomy

  Myocardial infarction

  Valvular disease

3.4% (4)

1.7% (2)

0.8% (1)

0.8% (1)

Peripheral Vascular

  Venous thrombosis with swelling, ulceration

3.4% (4)

3.4% (4)

Pulmonary

  Pleural fibrosis

  Pulmonary fibrosis

2.5% (3)

2.5% (3)

0.8% (1)

Musculoskeletal

  Deforming or erosive arthritis

  Muscle atrophy or weakness

2.5% (3)

1.7% (2)

0.8% (1)

Renal

  Proteinuria ≥3.5 gm/24hours

  Estimated or measured glomerular filtration rate<50%

2.5% (3)

1.7% (2)

0.8% (1)

Mucocutaneous

  Scarring chronic alopecia

1.7% (2)

1.7% (2)

Gastrointestinal

0

Conclusion:

Development of organ damage begins early in patients with SLE. In order to prevent damage accrual in the early stage of SLE it is necessary to identify which clinical manifestations and risk factors are associated with it.


Disclosure: M. Piga, None; F. Figus, None; F. Bellisai, None; S. Bettio, None; A. Bortoluzzi, None; L. Coladonato, None; F. Conti, None; A. Doria, None; M. Galeazzi, None; M. Govoni, None; F. Iannone, None; A. Iuliano, None; M. Mosca, None; I. Prevete, None; G. D. Sebastiani, None; F. R. Spinelli, None; C. Tani, None; A. Mathieu, None.

To cite this abstract in AMA style:

Piga M, Figus F, Bellisai F, Bettio S, Bortoluzzi A, Coladonato L, Conti F, Doria A, Galeazzi M, Govoni M, Iannone F, Iuliano A, Mosca M, Prevete I, Sebastiani GD, Spinelli FR, Tani C, Mathieu A. Factors Associated with Early Damage Accrual in Patients with Systemic Lupus Erythematosus: 12-Month Preliminary Results from the Inception Cohort of the Multicenter Early Lupus Project [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/factors-associated-with-early-damage-accrual-in-patients-with-systemic-lupus-erythematosus-12-month-preliminary-results-from-the-inception-cohort-of-the-multicenter-early-lupus-project/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/factors-associated-with-early-damage-accrual-in-patients-with-systemic-lupus-erythematosus-12-month-preliminary-results-from-the-inception-cohort-of-the-multicenter-early-lupus-project/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology